Skip to main content

Breast Cancer (TNBC) Licensing Deal Benchmarks

Median Upfront
$393M
Range: $219M - $612M
Total Deal Value
$2.5B
Range: $1.6B - $3.4B
Royalty Rate
13.4% - 21.9%
Tiered up to 25.9%
Dev Milestones
$526M
Range: $351M - $690M
Model Your Deal

Market Analysis

Triple-negative breast cancer remains one of the highest-value indication-modality combinations in oncology deal-making. Phase 2 TNBC deals, particularly for ADC approaches, carry a median total deal value of $2.5B with upfront payments between $219M and $612M. The unmet medical need and proven ADC success (Enhertu, Trodelvy) sustain strong licensing demand.

Milestone structures for TNBC assets allocate $526M to development milestones, $841M to regulatory milestones, and $736M to commercial milestones. The 16% upfront / 84% milestone split reflects the established clinical pathway and strong commercial precedent in breast cancer.

Royalty rates for TNBC licensing deals range from 13.4% to 21.9% at the base tier. ADC-based TNBC assets command the highest royalty rates due to demonstrated blockbuster potential and differentiated mechanisms of action. Combination approaches with IO agents are increasingly valued.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are benchmark deal terms for TNBC licensing?
Phase 2 TNBC deals average $393M upfront with $2.5B total deal value. ADC-based approaches command the highest valuations, followed by bispecifics and novel small molecules targeting TNBC-specific vulnerabilities.
How does the TNBC competitive landscape affect deal terms?
The success of Enhertu and Trodelvy has validated TNBC as a high-value target space, but also increased competitive pressure. Differentiated mechanisms, superior safety profiles, or activity in ADC-refractory patients command significant deal premiums.
What modalities dominate TNBC licensing deals?
ADCs lead TNBC deal volume and value, followed by bispecific antibodies and immunotherapy combinations. Novel payloads, topoisomerase inhibitor conjugates, and TROP2-targeting approaches are among the most actively licensed.
Are TNBC deal terms higher than other breast cancer subtypes?
TNBC deals generally command higher upfronts and total deal values than HR+ or HER2+ breast cancer deals due to greater unmet need and less crowded competitive landscape. However, HER2+ ADC deals can rival TNBC valuations when targeting novel epitopes.

Related Benchmarks

ADC Deal Benchmarks

View

Lung NSCLC Deal Terms

View

Bispecific Antibody Deals

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating